AbbVie acquires Allergan for $63B foreseeing Humira patent expiration
Category: #health  By Mateen Dalal  Date: 2019-06-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

AbbVie acquires Allergan for $63B foreseeing Humira patent expiration

American biopharmaceutical firm AbbVie Inc has reportedly announced its decision to acquire Botox-maker Allergan Plc in a $63 billion deal.

Apparently, this move would hand over the control of the profitable wrinkle remedy Botox to AbbVie, providing it enough time to explore new business opportunities before its top-selling arthritis drug Humira faces expiration of U.S. patents.

Evidently, Humira, one of the world’s bestselling drug, had managed to make $20 billion in 2018 but now faces rivalry from its cheaper versions in Europe. United States has been its most lucrative market so far, but the firm must tackle the expiration of its patents, which last until 2023.

Richard Gonzalez, AbbVie CEO and chairman, stated that the acquisition of Allergen could proceed on account of the funds raised by Humira. He admitted that Humira is helping to invest in assets that would substitute it over the long term. Gonzalez seems to be planning to lead the merged business through 2023.

Prominent in the list of those assets to be acquired is Allergan’s Botox, a purified form botulinum toxin that smoothens wrinkles and frown lines around the eyes and on the forehead by paralyzing various muscles. The drug is also known to handle an overactive bladder, treat chronic migraine headaches and provide other remedial benefits.

Citing reliable sources, when used as a cosmetic medication, patients need to pay for the drug out of pocket, shielding it from pricing burden that government health organizations and health insurers put on prescription drugs. Gonzalez also admitted that he does not anticipate another version of Botox.

Damien Conover, Morningstar analyst said that growing concerns regarding AbbVie’s future growth following biosimilar competition to Humira in 2023 would be moderately eased with the additional set of assets Allergan will offer.

According to Refinitiv data, Botox had close to $3.6 billion sales in 2018, with $1.55 billion coming from cosmetic applications. Both cosmetic and therapeutic Botox are anticipated to flourish, with expert analysts estimating total sales of about $3.9 billion in 2019 and nearing $6 billion by 2025.

 

Source Credits: https://www.reuters.com/article/us-allergan-m-a-abbvie/abbvie-looks-beyond-humira-with-63-billion-deal-for-botox-maker-allergan-idUSKCN1TQ15X

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Apple intends to inaugurate its new $1Bn campus in Texas by 2022
Apple intends to inaugurate its new $1Bn campus in Texas by 2022
By Mateen Dalal

The U.S – China trade war has been terrorizing the global economy since the dawn of 2018. It has affected the overall financial market and global supply chains. This ongoing trade war has had a negative impacted U.S. tech giant Apple’s sh...

Salesforce to use Amazon’s cloud to enhance call center services
Salesforce to use Amazon’s cloud to enhance call center services
By Mateen Dalal

Salesforce will use Amazon Web Services’ technology to turn customer’s spoken words into text.   The partnership will bring Amazon and Salesforce into more direct competition with call center technology service providers. Sales...

FDA warns Dollar Tree regarding the sale of imported adulterated drugs
FDA warns Dollar Tree regarding the sale of imported adulterated drugs
By Mateen Dalal

FDA’s new warning letter is asking Dollar Tree to ensure the company does not import adulterated medicines   Manufacturers mentioned in the letter include Hangzhou Zhongbo and Shanghai Weierya Daily Chemicals Reports confirm that the...